Spero Therapeutics (SPRO) Receivables (2022 - 2026)

Spero Therapeutics (SPRO) has 5 years of Receivables data on file, last reported at $44000.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 99.82% year-over-year to $44000.0; the trailing twelve-month figure through Mar 2026 stood at $44000.0 (down 99.82% YoY), and the FY2025 full-year result was $25.4 million, down 51.62% from the prior year.
• Receivables for Q1 2026 stood at $44000.0, down from $25.4 million in the prior quarter.
• Across five years, Receivables topped out at $55.5 million in Q2 2024 and bottomed at $44000.0 in Q1 2026.
• The 5-year median for Receivables is $26.9 million (2025), against an average of $31.5 million.
• The widest annual swing landed in 2023, when Receivables jumped 4576.85%; it then slumped 99.82% in 2026.
• A 5-year view of Receivables shows it stood at $1.1 million in 2022, then surged by 4576.85% to $50.7 million in 2023, then increased by 3.51% to $52.5 million in 2024, then tumbled by 51.62% to $25.4 million in 2025, then plunged by 99.83% to $44000.0 in 2026.
• The last three Receivables figures came in at $44000.0 (Q1 2026), $25.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.

Peer Comparison